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Patients with stage II colon cancer, as defined by pTNM/AJCC 2017, when analysed with regards to the risk of recur-
rence and to DFS and OS prolongation with adjuvant chemotherapy, make up a heterogenous patient population. 
That is why, a qualified oncologist, who makes a decision to apply adjuvant chemotherapy, taking into consideration 
the patient’s well-being, should formulate a post-operative strategy, the main objective of which will be to minimise 
the risk of cancer recurrence and to prolong survival. 
The author of this paper believes that adjuvant chemotherapy should be provided for every patient in the very high 
risk group (IIC) and high risk group (IIA/IIB MSI-L/MSS and inadequate lymphadenectomy and BRAF mutation), and 
also in the group of intermediate risk of cancer recurrence (IIA/IIB MSI-L/MSS with an adequate scope of lymphade-
nectomy and BRAF mutation as well as IIA MSI-L/MSS with inadequate scope of lymphadenectomy and lack of BRAF 
mutation), after obtaining the patient’s informed consent. In a situation when an oncologist is unable to obtain the 
result of microsatellite instability or the BRAF gene mutation, it would be advisable to refer the patient to a centre 
which has access to such tests; this would allow the adjuvant chemotherapy to have optimum application, which 
would by all means translate into the improvement of the treatment results in patients with colon cancer. 
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Introduction
Colorectal cancer (CRCA) belongs to the most frequen-
tly occurring malignant cancers, both in Poland and worl-
dwide. The tumour is most frequently located in the colon 
(C18 — colon cancer), understood by oncologists as a sum 
of the consecutive anatomical parts of the large intestine 
(caecum — C18.0, ascending colon — C18.2, hepatic flexure 
— C18.3, transverse colon — C18.4, splenic flexure — C18.5, 
a descending colon — C18.6, sigmoid colon — C18.7, sig-
moido-rectal ﬂexure — C19). Rectal cancer (C20), although 
also constituting a colorectal cancer, is treated separately 
by oncologists from the point of view of the differences in 
therapeutic management. Appendix cancer (C18.1) and anal 
cancer (C21) are the tumours with a completely different 
biology, and thus require a different treatment strategy; 
therefore, in oncological nomenclature, they are not inclu-
ded in the category of colorectal cancer [1].
A basic treatment method of colon cancer without di-
stant metastases seen in diagnostic imaging (M0) is a sur-
gical resection. However, about a half of the patients after 
radical resection of colon cancer will develop metastases 
within the next 5 years. This is due to the fact that in many 
cases the advancement stage of colon cancer, determined 
on the basis of the histopathological assessment of the post-
-operative specimen, is higher than the stage established 
on the basis of the diagnostic imaging. In 25% of cases with 
a clinically early cancer, a pathomorphologist is able to find 
some infiltration of pre-serous colon tissues (pT3) or visce-
ral peritoneum (pT4a) or neighbouring tissues and organs 
(pT4b), and, moreover, in 30–40% of cases a pathomorpho-
logist is able to find metastases in the regional lymph nodes 
(pN1a-b, pN2a-b stages), which were not found before the 
surgery [2]. That is why, in such cases, the main strategy in 
post-operative therapy is the treatment oriented towards 
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minimising the risk of cancer recurrence. This role, in the 
treatment of colon cancer, should be played by adjuvant 
chemotherapy.
The role of adjuvant chemotherapy
The objective of adjuvant chemotherapy (which com-
pletes the surgical resection) is to annihilate all cancer cells 
and micro-metastases in order to prevent the development 
of clinically overt distant metastases and to prolong disease-
-free survival (DFS), relapse-free survival (RFS), disease-spe-
cific survival (DSS) and overall survival (OS) [1].
Adjuvant chemotherapy may be taken into considera-
tion when a pathologist does not find any distant metastases 
in the post-operative specimen (pM0) and when the tumour 
resection was R0, i.e. was both microscopically and macro-
scopically radical. Radical resection means that the scope of 
the lymphadenectomy was optimal, i.e. at least 12 regional 
lymph nodes draining lymph from a specific section of the 
colon were removed by a surgeon and then assessed by a 
pathomorphologist under a microscope [1, 2].
Adjuvant chemotherapy in stage II colon cancer 
The fact that colon cancer patients benefit from the 
5-FU-based adjuvant chemotherapy was confirmed already 
in the 1980s and 1990s. A collective analysis published in 
2004 in the Journal of Clinical Oncology by Sharlene Gill et 
al. (7 studies: NCCTG, ECOG/NCCTG/INT, SWOG/INT0035, 
NCIC-CTG, FFCD, GIVIO) showed that the use of adjuvant 
chemotherapy after a radical resection increases the rate of 
a 5-year DFS to 67% (from 55%) and 5-year OS to 71% (from 
64%), in comparison with surgery alone; this translates into 
a relative reduction of recurrence risk (DFS) and the risk of 
death (OS) by 30% and 26% respectively [1]. These data 
however, concern, first of all stage III colon cancer patients 
(pN1–pN2b) as defined according to TNM/AJCC. The pro-
blem arises when an oncologist must make a decision about 
the treatment of a stage II patient (pT3–pT4b and pN0).
Two prospective trials (NACCP — Taal BG et al. 2001, 
Quasar — Gray R et al. 2007) showed an improvement in 
the 5-year survival, at a level of 3–8%, resulting from the 
application of adjuvant chemotherapy (in comparison with 
a group of patients undergoing surgery alone) in a group 
of patients with stage II colon cancer [1].
Some other studies (e.g. IMPACT B2 — Fang SH et al. 
2014, Cancer Care Ontario — Figueredo A et al. 2004, SEER/
MEDICARE — O’Connor ES et al. 2011) did not confirm the 
prolongation of overall survival in the adjuvant chemothe-
rapy arm as compared with surgery alone, yet these studies 
showed an improvement of DFS by 3% (Impact B2) and by 
5–10% (Cancer Care Ontario) in comparison with surgery 
alone [1].
It must be strongly emphasised that the collective ne-
gative analyses were drafted on the basis of the “old” cli-
nical trials. Additionally, in the largest collective negative 
overview, Cancer Care Ontario from 2011 (37 trials and 11 
meta-analyses), concerning a group of 20,317 patients with 
stage II according to AJCC, 5-FU/FA was used only in 2082 
cases (which makes up about 10%), whilst the remaining 
18,235 patients (about 90%) received nonoptimal adjuvant 
chemotherapy, e.g. 5-FU without biomodulation or oral 
5-FU (only 10–40% of the administered dose is absorbed) or 
5-FU+ semustine or 5-FU+ levamisole (increased myelotoxi-
city 5-FU and chemotherapy is discontinued more often) or 
unspecific immunotherapy or intraperitoneal 5-FU infusions 
or 5-FU infusions into the hepatic artery, which means that 
an improvement in the survival of the patients in the arm 
with adjuvant chemotherapy could not take place. In a re-
trospective analysis, SEER/MEDICRE only 3834 (about 20%) 
of stage II patients in the group of increased risk received 
adjuvant chemotherapy (out of 18,613 analysed patients) 
and, additionally, they were not randomised, as the decision 
to include chemotherapy depended on the oncologist; mo-
reover, within the chemotherapy group, the left-sided colon 
location of cancer was dominating (currently it is known 
that in this location, in 40–50% cases the CMS2 molecular 
subtype dominates — and it has better prognoses and 
longer OS and RFS) [1, 3].
In my opinion, the above negative meta-analyses and 
collective studies, with regards to some substantive draw-
backs (e.g. suboptimal adjuvant chemotherapy in the ad-
juvant therapy arm, the selection of patients with better 
prognoses etc.) do not contradict the statement that stage 
II colon cancer patients do not benefit from adjuvant che-
motherapy.
The opponents of adjuvant treatment in II stage of colon 
cancer also raise the issue of the toxicity of 5-FU- based 
chemotherapy, especially among persons above 70 years of 
age, referring to frequent events of stomatitis and leucopo-
enia as well as diarrhoea. It was proven that the G3 and G4 
toxicity (according to CTCAE criteria) of 5-FU chemotherapy 
increases the risk of death of a patient by about 1% — so 
such a low level of toxicity can be accepted [1].
The recently published analysis from the National Cancer 
Data Base from 2016 (Casadaban L. et al. [4]), covering 153 
110 II stage colon cancer patients (including 31,782 in the 
chemotherapy arm), showed that the benefits from adju-
vant chemotherapy such as an improvement in the overall 
survival (p < 0.001) are gained by the patients in the group 
of high and low risk of recurrence, and this is irrespective of 
their age (< 65 years of age and > 65 years of age). In 2015 
(Böckelman C. et al. [5]) an analysis was published on the 
basis of data concerning 1697 patients treated in 1999–2008 
in British Columbia (1286 = 76% patients in the high risk 
group and 411 = 24% low risk patients, out of whom 373 = 
29% and 51 = 12% respectively received adjuvant therapy), 
in which the benefit in OS was proven among the high risk 
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colorectal cancer patients treated with adjuvant therapy — 
prolongation of RFS, DSS and OS concerned the patients 
with pT4 stage. A similar result was rendered by an analysis 
published in 2016 on the basis of the data from the national 
cancer register in the Netherlands (Verhoeff SR et al. [6]). 
It was carried out on a population of 4940 II clinical stage 
colorectal cancer patients with clinical features of high risk 
(out of 10,935 colorectal cancer patients in clinical stage II 
in whose case the diagnosis was established in 2008–2012 
and who were treated surgically) — the benefits in adjuvant 
therapy were observed solely in the patients with pT4 stage 
— the risk of death in patients in the pT4 stage receiving 
chemotherapy was lower in comparison with patients who 
did not receive chemotherapy: the 3-year survival rate was 
91% and 73% respectively, HR 0.43, 95% CI 0.28–0.66.
The use of adjuvant chemotherapy in II stage colon can-
cer may be determined either by clinical and pathological 
factors or by clinical and molecular factors. The first group 
of factors comprises: 1) pT4 stage of cancer advancement 
(the most important factor); 2) inadequate scope of lym-
phadenectomy (the lack of lymph nodes assessment in the 
post-operative specimen or the number of resected and 
assessed lymph nodes lower than 12); 3) G3 cancer grade 
and small-cell cancer; 4) the involvement of the peritumo-
ral lymph and blood vessels; 5) R1 resection; 6) patients 
operated on account of an intestinal perforation or ileus. 
The second group of factors comprises the evaluation of 
microsatellite instability (MSI), which is the marker of the 
genetic mechanism of mismatch repair (MMR — mutator 
genes — e.g. MLH1, MSH2) and the BRAF gene mutation. 
Depending on the rate of mismatch microsatellite regions, 
detected in specific tests, the cancer can be classified as 
characterised with MSI-high (MSI-H) or MSI-low (MSI-L) [1, 8].
Microsatellite instability is a feature characteristic of 
not only hereditary nonpolyposis colorectal cancer (Lynch 
syndrome, HNPCC), but it also occurs in morphological-mo-
lecular subtypes of sporadic cancer, in which carcinogenesis 
comprise an epigenetic disorder consisting of silencing one 
or more MMR genes — most frequently the MLH1 gene. 
MMR deficiency (dMMR), the main marker of which is MSI-H 
— is found in about 20% of patients with sporadic colorectal 
cancer. It must be pointed out that in colon cancer, dMMR is 
connected with better prognosis and a worse response to 
5-FU-based chemotherapy (Tougeron D et al. [8]).
The type of cancer in which MSI is not found, is referred to 
as a microsatellite stable (MSS) or a MMR proficient (pMMR). 
In the morphological-molecular subtype (which is the most 
frequent in sporadic colorectal cancer), usually chromosomal 
instability (CIN) is found at the level of the loss of heterozy-
gosity (LOH), most often in 18q, 2p, 5q, 17p. Chromosomal 
instability is an independent prognostic survival marker in 
stage II and III colorectal cancer (according to TNM/AJCC) with 
respect to DFS (p < 0.001) and OS (p < 0.0076) [9].
In a collective analysis of a few trials, such as, among 
others: Pan-European Trials in Adjuvant Colon Cancer (PE-
TACC III), the European Organization for Research and Tre-
atment of Cancer (EORTC) 40993 and the Swiss Group for 
Clinical Cancer Research (SAKK), a molecular marker, such 
as MSI-H, was found in 22% of stage II colon cancer patients. 
The multivariate analysis showed better prognosis in pa-
tients with stage II MSI-H cancer with regards to the impro-
vement of the overall survival (OS) and RFS in comparison 
to patients with MSS type cancer (HR = 0.45; p = 0.0003). In 
the stage II cancer patients (according to pTNM/AJCC) in 
the MSI-H subgroup, the BRAF gene mutations were domi-
nant (63%), but only in the MSI-L and MSS subgroups did 
the presence of BRAF mutations result in a shorter overall 
survival. This led the authors to the conclusion that MSI-H 
may render a “protective effect” for recurrence in relation to 
the negative effect of the BRAF mutation [10].
On the basis of the results of the above studies, one can 
assume that the presence of MSI-H in stage II colon cancer 
has a positive prognostic significance. Nevertheless, the 
data from the American register, SEER-NCI, show that 5-year 
survival in patients with stage IIC colon cancer is much worse 
(37%) than in the case of stage IIIA (T1–2N1/T1N2a — 73%), 
and close to stage IIIB (pT3–T4aN1/ pT2–T3N2a/pT1–T2N2b 
— 45%) [2]. Therefore it is beyond all doubt that among the 
patients with stage II C colorectal cancer, there are cases of 
MSI-H, which should definitely be treated with adjuvant 
chemotherapy.
However, today the majority of oncologists, when quali-
fying patients to adjuvant therapy, base their decisions on 
clinical and pathological parameters; whilst these parame-
ters “tend to” pick a small number of patients with stage II 
colon cancer who should be treated with adjuvant therapy, 
they are unable at the same time to determine the degree of 
recurrence risk in an individual case. O’Connell et al [11] in 
2010 publish the best — in my opinion to date — multiva-
riate analysis of the dependence of gene panel expression 
which seem to be connected with the risk of recurrence 
(RSG — recurrence score gene panel) and with response 
to 5-FU/FA adjuvant therapy (TSG —treatment score gene 
panel). The RNA extracted from paraffin blocks in 1581 pa-
tients with colorectal cancer in stages II and III according 
to pTNM/AJCC, was studied with the reverse polymerase 
chain reaction test (RT-qPCR). Then the RSG panel consisting 
of 12 genes (7 cancer genes + 5 reference genes) and TSG 
panel consisting of 11 genes (6 genes of the 5-FU response 
+ 5 reference genes) were determined and the risk of colo-
rectal cancer recurrence and benefit from the use of 5-FU/
FA adjuvant chemotherapy were calculated with statistical 
methods. On the basis of these calculations, the algorithms 
for evaluation of the risk of recurrence and benefits from 
chemotherapy were constructed and they were used for the 
identification of the groups of low, intermediate and high 
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recurrence risk as well as the benefits in the administration 
of 5-FU/FA adjuvant chemotherapy. The cancer recurrence 
score (RS) was calculated with the cut-off thresholds for 
the risk groups in stage II being: low RS < 30, intermediate 
RS 31–40 and high RS ≥ 41, which translated into a 3-year 
cancer recurrence risk of 8%, 11% and 25% patients. The 
difference between the low and intermediate groups was 
not statistically significant. The cut-off thresholds for the 
benefits in the use of 5-FU/FA adjuvant chemotherapy, after 
3 years were, in the low, intermediate and high risk groups: 
(–)3%, 3% and 8% respectively [11, 12].
In Polish conditions, the evaluation of the recurrence 
score (RS) is rarely possible, and that is why the author of 
this paper proposed a simplified model for qualification of 
adjuvant therapy in stage II colon cancer patients (accor-
ding to pTNM/AJCC). This model is based on the analysis 
of the MSI BRAF gene mutation as well as the T3–pT4 stage 
and lymphadenectomy scope. Figure 1 presents a modified 
treatment algorithm which takes into consideration these 
4 parameters and should be of some assistance in taking 
decisions about the application of adjuvant chemotherapy.
In accordance with Figure 1 and assuming a minimum 
positive effect of chemotherapy on the level of 3–8%, stage II 
colon cancer patients with a low recurrence risk (IIA/IIB MSI-H 
irrespectively of the BRAF gene mutation or IIA MSI-L/MSS and 
optimum lymphadenectomy and no BRAF mutation) do not 
require adjuvant chemotherapy at all. The stage II colon can-
cer patients with a high recurrence risk in turn (IIA/IIB MSI-L/
MSS and inadequate lymphadenectomy and BRAF mutation) 
will benefit from the adjuvant use of 5-FU/FA or capecitabine. 
In the case of post-operative diagnosis of colon cancer IIA/IIB 
MSI-L/MSS with adequate scope of lymphadenectomy and 
BRAF mutation, and IIA MSI-L/MSS with inadequate lympha-
denectomy scope and lack of BRAF mutation, the decision to 
apply adjuvant chemotherapy should be taken by a clinical 
oncologist, taking into consideration other factors (such as 
age, comorbidities, other existing clinical or pathological risk 
factors etc.) and — respecting the decision of the patient — 
the author of this paper, on the basis of his own experience 
is convinced of the appropriateness of the use of adjuvant 
chemotherapy in this group of patients with an intermediate 
risk of recurrence. Stage IIC colon cancer patients should be 
given a 2-drug regimen — FOLFOX or XELOX [1, 13]. 
In 2015 the characteristic features for molecular subty-
pes of colorectal cancer were published (CMS — The con-
sensus molecular subtypes of CRC) [3, 14]. These criteria are 
summarised in Table I.
A routine analyses of the cases of colorectal cancer (co-
lon cancer and rectal cancer) carried out according to the 
CMS molecular criteria will allow for a more precise deter-
mination of the population of stage II patients who would 
benefit from adjuvant chemotherapy.
Conclusions 
Analysing the problem with a view to a risk of cancer recur-
rence as well as DFS and OS prolongation with the use of adju-
vant chemotherapy, stage II colon cancer patients (according 
to pTNM/AJCC) make up a heterogenous group of patients.
Figure 1. A modified algorithm helpful for the selection of adjuvant chemotherapy in patients with stage II colon cancer as defined by pTNM/AJCC
Stage according to TNM/AJCC — 8. ed. 2017 The number of 
lymph nodes assessed
BRAF gene
mutation
Type of adjuvant
chemotherapy
Stage IIA (pT3N0) + MSI-H
Stage IIB (pT4aN0) + MSI-H
Stage IIA + MSS lub MSI-L
Stage IIB + MSS lub MSI-L
Stage IIC (pT4bN0)
≥ 12
< 12
≥ 12
< 12
–
–
+
–
–
+
+
No
chemotherapy
5-FU/FA
or
Capecitabine
FOLFOX
or
XELOX
MSI — microsatelite instability (dMMR); MSS — microsatelite stable (pMMR).       up to the decision of the clinical oncologist
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I believe that adjuvant chemotherapy should be provided 
for every patient in the very high risk (IIC) and high risk group 
(IIA/IIB MSI-L/MSS and inadequate lymphadenectomy and 
BRAF mutation), but also from the group of intermediate risk 
of cancer recurrence (IIA/IIB MSI-L/MSS with adequate scope 
of lymphadenectomy and BRAF mutation and IIA MSI-L/MSS 
with inadequate lymphadenectomy and lack of BRAF muta-
tion) — upon obtaining the patient’s informed consent. If the 
oncologist does not have any possibility to obtain the results 
of the microsatellite instability test or BRAF gene mutation, it 
would be advisable to transfer the patient to a centre which has 
access to such a test through which adjuvant chemotherapy 
could optimally be used. This will definitely translate into an 
improvement of the treatment results for colon cancer patients.
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Table I. Molecular and clinical features of colorectal cancer according to the CMS classification and the possibilities of studies of the personalised 
therapy suggested on the basis of this classification
CMS1 (MSI Immune — 
MSI immunogenic)
CMS2 (Canonical — basic 
epithelial)
CMS3 (Metabolic 
— connected with 
the deregulation of 
metabolic pathways)
CMS4 (Mesenchymal 
— micro-environment-
dependent)
Prevalence ~15 ~40 ~15 ~30
Tumour location within the 
large intestine 
Right-side of colon 
location is dominating 
Left-side of colon 
and anal location is 
dominating 
Right-side of colon 
location is dominating
Left-side of colon 
and anal location is 
dominating
Cancer cells features Hyper-mutated and 
hyper-methylated, MSI, 
dominance of mutated 
BRAF
CIN, MSS, EGFR+, 
excessive ERRB2 
regulation 
Mixed MSI/MSS, CIN, 
deregulation of metabolic 
pathways of mutated 
KRAS
MSS, CIN, disordered 
interactions between 
epithelial and stromal 
cells 
Microenvironment cell 
properties 
Numerous cytotoxic and 
helper lymphocytes T and 
NK cells
Small infiltrations of 
immunological and 
stromal cells 
Small infiltrations of 
immunological and 
stromal cells 
Numerous stromal cells, 
numerous suppressor 
cells T-reg. lymphocytes, 
B lymphocytes, myeloid-
derived cells
Prognosis Longer RFS, after 
recurrence shorter OS
Longer RFS and OS Longer RFS and OS Shorter RFS and OS
Medication to be used in 
clinical trials 
PD-1 and PD-L1 
inhibitors; BRAF signalling 
pathway inhibitors
Signalling pathway 
inhibitors through EGFR, 
inhibiting overexpression 
of proteins from the HER 
family 
PanRAF and MEK 
signalling pathway 
inhibitors in association 
with inhibitors of 
enzymatic paths 
Associating immune-
stimulating medication 
with immunosuppression 
